<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03739866</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-200-4072</org_study_id>
    <nct_id>NCT03739866</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Antiviral Activity of Lenacapavir Administered Subcutaneously in HIV-1 Infected Adults</brief_title>
  <official_title>A Phase 1b Randomized, Double-Blinded, Placebo Controlled, Multi-Cohort Study of the Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has 2 parts: Part A (Cohorts 1-5) and Part B (Cohorts 6-8).

      The primary objectives of this study are:

      Part A: To evaluate the short-term antiviral activity of lenacapavir (formerly GS-6207)
      compared to placebo in HIV-1 infected adults who are antiretroviral treatment naive or are
      experienced but capsid inhibitor (CAI) naive.

      Part B: To evaluate the short-term antiviral activity of tenofovir alafenamide (TAF) with
      respect to the maximum reduction of plasma HIV-1 RNA (log10 copies/mL) from Day 1 through Day
      10 in HIV-1 infected adult subjects who are antiretroviral treatment naïve or are experienced
      but without resistance to TAF.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 26, 2018</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">November 14, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Reduction of Plasma HIV-1 RNA (log10 copies/mL) from Day 1 through Day 10</measure>
    <time_frame>Day 1 through Day 10</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</measure>
    <time_frame>Up to 225 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Graded Laboratory Abnormalities</measure>
    <time_frame>Up to 225 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUCinf of lenacapavir</measure>
    <time_frame>Predose and 1, 2, 4, 8, 12, and 24 hours post dose on Day 1; Days 3, 4, 7, 8, 9, 10, 14, 29, 43, 57, 85, 113, 141, 169, 197 and 225</time_frame>
    <description>AUCinf is defined as the concentration of drug extrapolated to infinite time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUClast of lenacapavir</measure>
    <time_frame>Predose and 1, 2, 4, 8, 12, and 24 hours post dose on Day 1; Days 3, 4, 7, 8, 9, 10, 14, 29, 43, 57, 85, 113, 141, 169, 197 and 225</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of lenacapavir</measure>
    <time_frame>Predose and 1, 2, 4, 8, 12, and 24 hours post dose on Day 1; Days 3, 4, 7, 8, 9, 10, 14, 29, 43, 57, 85, 113, 141, 169, 197 and 225</time_frame>
    <description>Cmax is defined as the maximum observed concentration of drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation Between Ct (Concentration at Day 10) of lenacapavir and the Maximum Reduction of Plasma HIV-1 RNA (log10 copies/mL) from Baseline through Day 10 Estimated using the Pearson Correlation Analysis</measure>
    <time_frame>Baseline through Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Ever Achieving HIV-1 RNA &lt; 50 copies/mL by Day 10</measure>
    <time_frame>Day 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Any Emergence of Capsid Inhibitor Resistance</measure>
    <time_frame>Up to 225 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experience Any Emergence of TAF Resistance</measure>
    <time_frame>Up to 225 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameter: AUCinf of TAF (and its metabolite)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 and 48 hours post dose on Day 1; Days 4, 5, (if possible), 6 (if possible), 7, 8, 9, and 10</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: AUClast of TAF (and its metabolite)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 and 48 hours post dose on Day 1; Days 4, 5, (if possible), 6 (if possible), 7, 8, 9, and 10</time_frame>
    <description>AUClast is defined as the concentration of drug from time zero to the last observable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Parameter: Cmax of TAF (and its metabolite)</measure>
    <time_frame>Predose and 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 and 48 hours post dose on Day 1; Days 4, 5, (if possible), 6 (if possible), 7, 8, 9, and 10</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Lenacapavir (Part A)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in Cohort 1 will receive a single dose of lenacapavir 150 mg on Day 1. Following review of preliminary safety and pharmacokinetic (PK) data, participants will be enrolled in Cohorts 2-3 to receive a single dose of lenacapavir up to 450 mg on Day 1 or Cohorts 4-5 to receive a single dose of lenacapavir up to 900 mg on Day 1.
After completion of all assessments, at Day 10, participants will receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive a single dose of placebo on Day 1.
After completion of all assessments, at Day 10, participants will receive B/F/TAF for the remainder of the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TAF (Part B)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a single dose of TAF 200 mg on Day 1. Following review of preliminary safety and PK data, participants will be enrolled in Cohorts 7-8 to receive a single dose of TAF up to 600 mg on Day 1.
After completion of all assessments, at Day 10, participants will receive bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) for the remainder of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenacapavir</intervention_name>
    <description>Administered subcutaneously in the abdomen</description>
    <arm_group_label>Lenacapavir (Part A)</arm_group_label>
    <other_name>GS-6207</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered subcutaneously in the abdomen</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/F/TAF</intervention_name>
    <description>50/200/25 mg tablets administered orally once daily</description>
    <arm_group_label>Lenacapavir (Part A)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>TAF (Part B)</arm_group_label>
    <other_name>Biktarvy®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAF</intervention_name>
    <description>Tablets administered orally</description>
    <arm_group_label>TAF (Part B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Plasma HIV-1 RNA ≥ 5,000 copies/mL but ≤ 400,000 copies/mL and CD4+ cell count &gt; 200
             cells/mm^3

          -  Treatment naive or experienced but CAI and integrase strand transfer inhibitor (INSTI)
             naïve, and have not received any antiretroviral therapy (ART) within 12 weeks of
             screening

          -  Screening genotype report must show sensitivity to B/F/TAF to allow its initiation on
             Day 10

          -  Screening genotype report must show sensitivity to at least one agent in either
             non-nucleoside reverse transcriptase inhibitor (NNRTI) or protease inhibitor (PI)
             class to allow its use as part of standard of care oral antiretroviral treatment in
             the future

          -  Have adequate renal function (estimated glomerular filtration rate ≥ 70 mL/min)

          -  No clinically significant abnormalities in ECG at Screening

          -  Willing to initiate B/F/TAF on Day 10 after completion of all assessments

        Key Exclusion Criteria:

          -  Pregnant or lactating

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ruane Clinical Research Group, Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mills Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>One Community</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Lundquist Institute for BioMedical Innovation at Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center PA</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803-1851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072-3436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Arms, Inc., DBA Prism Health North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Infectious Diseases Consultants, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarrant County Infectious Disease Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center, INC (dba Gordon E. Crofoot MD PA)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 2, 2018</study_first_submitted>
  <study_first_submitted_qc>November 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

